Neuren Pharmaceuticals Limited (NEU.AX) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from published company financials, balance sheet as of 2025-12-31. NEU.AX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 10.68% | 30.00% | Pass |
| Non-permissible income | 18.81% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 86.37% | 33.00% | Fail |
| Non-liquid assets | 13.50% | at least 20.00% | Fail |
| Non-permissible income | 18.81% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 86.37% | 33.33% | Fail |
| Accounts receivable | 86.50% | 33.33% | Fail |
| Non-permissible income | 18.81% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 86.37% | 33.33% | Fail |
| Accounts receivable | 86.50% | 50.00% | Fail |
| Non-permissible income | 18.81% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 13.95% | 33.00% | Pass |
| Accounts receivable | 0.02% | 33.00% | Pass |
| Non-permissible income | 18.81% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 13.06% | 49.00% | Pass |
| Accounts receivable | 0.02% | 49.00% | Pass |
| Non-permissible income | 18.81% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 13.06% | 33.33% | Pass |
| Accounts receivable | 13.08% | 49.00% | Pass |
| Non-permissible income | 18.81% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 47.40 | NEUTRAL |
| Stochastic %K (14) | 24.43 | NEUTRAL |
| CCI (20) | -57.99 | NEUTRAL |
| Williams %R (14) | -75.57 | NEUTRAL |
| MACD (12,26,9) | -0.24 | SELL |
| ROC (10) | -0.98 | SELL |
| Momentum (10) | -0.20 | SELL |
| EMA (10) | 20.50 | SELL |
| SMA (10) | 20.26 | SELL |
| EMA (20) | 20.66 | SELL |
| SMA (20) | 21.18 | SELL |
| EMA (30) | 20.41 | SELL |
| SMA (30) | 21.46 | SELL |
| EMA (50) | 19.52 | BUY |
| SMA (50) | 19.64 | BUY |
| EMA (100) | 17.87 | BUY |
| SMA (100) | 16.54 | BUY |
| EMA (200) | 17.62 | BUY |
| SMA (200) | 15.93 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.